Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
Fields of Study & Subjects
Diabetes Treatment and Management
Diabetes
Cardiovascular Risks
and Lipoproteins
Hyperglycemia and glycemic control in critically ill and hospitalized patients
Publication details
- Journal / source
- The Lancet
- Publisher
- Elsevier BV
- Volume
- 407
- Issue
- 10534
- Pages
- 1147–1160
- Publication date
- 26 February 2026
- Language
- EN